Highlightll Pharma Files for HKEX Listing, Core Product TLL-018 in Phase III Registrational Trials

NewTimeSpace News: As disclosed by HKEX, Hangzhou Highlightll Pharmaceutical Co., Ltd. filed its Main Board listing application with the Hong Kong Stock Exchange on June 8, 2026, with CICC and China Merchants Bank International serving as joint sponsors.
Established in 2017, Highlightll Pharmaceutical is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of treatments for autoimmune and inflammatory diseases. As of the latest practicable date, the company has discovered seven small-molecule drug candidates, four of which are in clinical development. Its core product, TLL-018 (Girocitinib), is a selective TYK2/JAK1 inhibitor, currently advancing two Phase III registrational trials in China for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA).
The company’s neurodegenerative disease pipeline also features two clinical-stage candidates: TLL-041/BHV-8000, a brain-penetrant selective TYK2/JAK1 inhibitor, and HL-400, an NLRP3 inhibitor targeting Parkinson’s disease. The company has yet to generate revenue from commercial product sales and has remained profitable throughout the track record period.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.